Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05017662
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Overview
The purpose of the protocol is to evaluate the long-term safety of medicine 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072 or 177Lu-OPS201) for patients who have previously received 177Lu-satoreotide tetraxetan in the clinical study OPS-C-001 / D-FR-01072-001.
Sponsor
Ariceum Therapeutics GmbH
Phase
N/A
Contacts
Ariceum Chief Medical Officer (STUDY_DIRECTOR)
ClinicalTrials.gov
NCT05017662Eligibility
Inclusion
- Participant must have received at least one infusion of 177Lu-IPN01072 in Study OPS-C-001
Exclusion
- \- There are no exclusion criteria in this safety surveillance study.
Share your feedback
Help us improve your experience